RxDoctor Payments Data

Keith Coward, MD

Internal Medicine · Clinton, ARNPI 1710982871

Payments from drug & device makers

$1,997in general payments, 2019–2025

Across 123 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$408
  • Novo Nordisk$389
  • Lilly USA, LLC$237
  • Amgen$216
  • Amarin Pharma, Inc.$145
  • Boehringer Ingelheim$133
  • plus $469 from 15 others

What the payments were for

  • Food & beverage$1,997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,997 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$10,745
Medicare patients
59
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin424$253,188
EliquisApixaban370$161,924
OzempicSemaglutide114$118,734
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$64,192
MounjaroTirzepatide49$59,633
EntrestoSacubitril/Valsartan121$50,803
XareltoRivaroxaban86$38,739
TrulicityDulaglutide38$38,187
Tresiba Flextouch U-200Insulin Degludec29$26,762
FarxigaDapagliflozin Propanediol36$25,454
Tresiba Flextouch U-100Insulin Degludec42$20,757
LinzessLinaclotide34$18,338
Breo ElliptaFluticasone/Vilanterol35$15,546
RybelsusSemaglutide11$15,511
VascepaIcosapent Ethyl35$12,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$133$262,086441 claims
PfizerEliquis$13$161,924370 claims
Novo NordiskOzempic, Rybelsus, Tresiba$389$138,903138 claims
Lilly USA, LLCMounjaro, Trulicity$237$97,82087 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$72$83,893137 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$408$53,485115 claims
Johnson & JohnsonXarelto$23$38,73986 claims
MerckJanuvia$60$7,56128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Clinton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →